Free Access
Neurodegenerative Dis 2012;10:60–63

A Persistent Stress Response to Impeded Axonal Transport Leads to Accumulation of Amyloid-β in the Endoplasmic Reticulum, and Is a Probable Cause of Sporadic Alzheimer’s Disease

Muresan V. · Muresan Z.
Department of Pharmacology and Physiology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, N.J., USA
email Corresponding Author

 goto top of outline Key Words

  • Alzheimer’s disease
  • Amyloid-β precursor protein
  • Amyloid-β peptide
  • Axonal transport
  • Kinesin
  • Endoplasmic reticulum stress
  • Protein phosphorylation
  • Mechanism of neurodegenerative diseases

 goto top of outline Abstract

Background and Objective: Could a normal – but persistent – stress response to impeded axonal transport lead to late-onset Alzheimer’s disease (AD)? Our results offer an affirmative answer, suggesting a mechanism for the abnormal production of amyloid-β (Aβ), triggered by the slowed axonal transport at old age. We hypothesize that Aβ precursor protein (APP) is a sensor at the endoplasmic reticulum (ER) that detects, and signals to the nucleus, abnormalities in axonal transport. When persistently activated, due to chronically slowed-down transport, this signaling pathway leads to accumulation of Aβ within the ER. Methods and Results: We tested this hypothesis with the neuronal cell line CAD. We show that, normally, a fraction of APP is transported into neurites by recruiting kinesin-1 via the adaptor protein, Fe65. Under conditions that block kinesin-1-dependent transport, APP, Fe65 and kinesin-1 accumulate in the soma, and form a complex at the ER. This complex recruits active c-Jun N-terminal kinase (JNK), which phosphorylates APP at Thr668. This phosphorylation increases the cleavage of APP by the amyloidogenic pathway, which generates Aβ within the ER lumen, and releases Fe65 into the cytoplasm. Part of the released Fe65 translocates into the nucleus, likely to initiate a gene transcription response to arrested transport. Prolonged arrest of kinesin-1-dependent transport could thus lead to accumulation and oligomerization of Aβ in the ER. Conclusion: These results support a model where the APP:Fe65 complex is a sensor at the ER for detecting the increased level of kinesin-1 caused by halted transport, which signals to the nucleus, while concomitantly generating an oligomerization-prone pool of Aβ in the ER. Our hypothesis could thus explain a pathogenic mechanism in AD.

Copyright © 2011 S. Karger AG, Basel

 goto top of outline References
  1. Herrup K: Reimagining Alzheimer’s disease – An age-based hypothesis. J Neurosci 2010;30:16755–16762.
  2. Muresan V, Muresan Z: Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer’s disease? Future Neurol 2009;4:761–773.
  3. Qi Y, Wang JK, McMillian M, Chikaraishi DM: Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation. J Neurosci 1997;17:1217–1225.
  4. Muresan V, Varvel NH, Lamb BT, Muresan Z: The cleavage products of amyloid-beta precursor protein are sorted to distinct carrier vesicles that are independently transported within neurites. J Neurosci 2009;29:3565–3578.
  5. Muresan Z, Muresan V: A phosphorylated, carboxy-terminal fragment of beta-amyloid precursor protein localizes to the splicing factor compartment. Hum Mol Genet 2004;13:475–488.
  6. Muresan Z, Muresan V: c-Jun NH2-terminal kinase-interacting protein-3 facilitates phosphorylation and controls localization of amyloid-beta precursor protein. J Neurosci 2005;25:3741–3751.
  7. Muresan Z, Muresan V: Coordinated transport of phosphorylated amyloid-beta precursor protein and c-Jun NH2-terminal kinase-interacting protein-1. J Cell Biol 2005;171:615–625.
  8. Muresan Z, Muresan V: Neuritic deposits of amyloid-β peptide in a subpopulation of central nervous system-derived neuronal cells. Mol Cell Biol 2006;26:4982–4997.
  9. Muresan Z, Muresan V: The amyloid-beta precursor protein is phosphorylated via distinct pathways during differentiation, mitosis, stress, and degeneration. Mol Biol Cell 2007;18:3835–3844.
  10. Muresan Z, Muresan V: Seeding neuritic plaques from the distance: a possible role for brainstem neurons in the development of Alzheimer’s disease pathology. Neurodegener Dis 2008;5:250–253.

    External Resources

  11. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR: Intraneuronal abeta42 accumulation in human brain. Am J Pathol 2000;156:15–20.
  12. Muresan Z, Muresan V: The phosphorylated, carboxy-terminal fragments of amyloid-β precursor protein are targeted to multiple intraneuronal locations by destination-specific molecular motors and adaptor proteins. Annu Meet Soc Neurosci, Chicago, October 17–21, 2009.
  13. Muresan Z, Muresan V: Kinesin-1 is a signaling protein that recruits active kinase complexes and directly participates in substrate phosphorylation. Annu Meet Am Soc Cell Biol, San Francisco, December 13–17, 2008.
  14. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, Tsai LH: APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 2003;163:83–95.
  15. Radzimanowski J, Simon B, Sattler M, Beyreuther K, Sinning I, Wild K: Structure of the intracellular domain of the amyloid precursor protein in complex with Fe65-PTB2. EMBO Rep 2008;9:1134–1140.
  16. Zhou D, Zambrano N, Russo T, D’Adamio L: Phosphorylation of a tyrosine in the amyloid-beta protein precursor intracellular domain inhibits Fe65 binding and signaling. J Alzheimers Dis 2009;16:301–307.
  17. Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG: Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 2002;110:55–67.
  18. Cao X, Sudhof TC: A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001;293:115–120.
  19. He W, Lu Y, Qahwash I, Hu XY, Chang A, Yan R: Reticulon family members modulate bace1 activity and amyloid-beta peptide generation. Nat Med 2004;10:959–965.
  20. Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I: Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer’s disease-linked mutations. Cell 2006;126:981–993.

 goto top of outline Author Contacts

Zoia Muresan
Department of Pharmacology and Physiology
University of Medicine and Dentistry of New Jersey, New Jersey Medical School
185 South Orange Avenue, MSB, I-665, Newark, NJ 07101-1709 (USA)
Tel. +1 973 972 4385, E-Mail

 goto top of outline Article Information

Received: June 28, 2011
Accepted after revision: September 3, 2011
Published online: December 7, 2011
Number of Print Pages : 4
Number of Figures : 4, Number of Tables : 0, Number of References : 20

 goto top of outline Publication Details

Neurodegenerative Diseases

Vol. 10, No. 1-4, Year 2012 (Cover Date: April 2012)

Journal Editor: Nitsch R.M. (Zürich), Hock C. (Zürich)
ISSN: 1660-2854 (Print), eISSN: 1660-2862 (Online)

For additional information:

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.